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Background: Intermittent Preventive Treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is
widely used for the control of malaria in pregnancy in Africa. The emergence of resistance to SP is a concern
requiring monitoring the effectiveness of SP for IPTp.
Methods: This was an in-vivo efficacy study to determine the parasitological treatment response and the duration
of post-treatment prophylaxis among asymptomatic pregnant women receiving SP as part of IPTp in Mali and
Burkina-Faso. The primary outcome was the PCR-unadjusted % of patients with parasites recurrence by day 42
defined as a positive diagnostic test by malaria smear at any visit between days 4 and 42. Treatment failure was
based on the standard World Health Organization criteria. The therapeutic response was estimated using the
Kaplan-Meier curve.
Results: A total of 580 women were enrolled in Mali (N=268) and Burkina-Faso (N=312) and followed weekly for 42
days. Among these, 94.3% completed the follow-up. The PCR-unadjusted cumulative risk of recurrence by day 42
was 4.9% overall, and 3.2% and 6.5% in Mali and Burkina Faso respectively (Hazard Ratio [HR] =2.14, 95%, CI [0.93-4.90];
P=0.070), and higher among the primi– and secundigravida (6.4%) than multigravida (2.2%, HR=3.01 [1.04-8.69];
P=0.042). The PCR-adjusted failure risk was 1.1% overall (Mali 0.8%, Burkina-Faso 1.4%). The frequencies (95% CI) of the
dhfr double and triple mutant and dhps 437 and 540 alleles mutant genotype at enrolment were 24.2% (23.7-25.0),
4.7% (4.4-5.0), and 21.4% (20.8-22.0) and 0.37% (0.29-0.44) in Mali, and 7.1% (6.5-7.7), 44.9% (43.8-46.0) and 75.3%
(74.5-76.2) and 0% in Burkina-Faso, respectively. There were no dhfr 164L or dhps 581G mutations.
Conclusion: SP remains effective at clearing existing infections when provided as IPTp to asymptomatic pregnant
women in Mali and Burkina. Continued monitoring of IPTp-SP effectiveness, including of the impact on birth
parameters in this region is essential.
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In sub-Saharan Africa, malaria places 31 million pregnan-
cies at risk of maternal anaemia and intrauterine growth
retardation resulting in low birth weight (LBW) annually
[1-3]. In this region, the World Health Organization (WHO)
recommends Intermittent Preventive Treatment in preg-
nancy (IPTp) with at least two doses of sulphadoxine-
pyrimethamine (SP) for the control of malaria in pregnancy
[4]. The two-dose IPTp-SP regimen has been shown to be
very effective and is associated with an average reduction
in the risk of LBW of 29% [2]. More recent meta-analysis
has shown that this can be enhanced further by providing
three or more doses of SP at monthly intervals during
pregnancy [5].
However, the emergence of SP resistance is potentially
reducing the effectiveness of SP. In the early 2000s, SP
was abandoned as first line treatment for symptomatic
malaria in the general population in sub-Saharan Africa
in favour of more effective artemisinin-based combination
therapy (ACT). Because IPTp with SP continued to pro-
vide significant protection in areas with moderate to high
parasite resistance [2], SP continues to be recommended
by WHO for IPTp, and is currently the only anti-malarial
used for this indication [6]. The degree of SP resistance
correlates with the frequency of single nucleotide poly-
morphisms (SNPs) that encode amino acid substitutions
in the dihydrofolate reductase (dhfr) and dihydropteroate
synthetase (dhps) genes of Plasmodium falciparum. High
grade resistance is a particular concern in eastern and
southern Africa [7], where high frequencies of parasites
bearing haplotypes with three mutations in dhfr (encoding
the N51I, C59R, and S108N) and two in dhps (encoding
the A437G and K540E substitutions) exist, especially if the
additional dhfr164L or dhps581G mutations occur [8,9].
The latter has recently been associated with poor birth
outcomes in IPTp-SP recipients [10], although this as-
sociation has not yet been confirmed in other studies
in eastern and southern Africa [11-13].
In contrast, the parasite populations in western Africa
seem to be mostly sensitive to SP [7,14-16], and IPTp-SP
has proven to be highly effective and efficacious in clinical
trials and observational studies [5,15]. However, spread of
SP resistance from eastern and southern Africa, or the de
novo development of high-level SP resistance may occur
and monitoring of the effectiveness of SP when employed
as IPTp is essential.
Despite this need, there are no internationally stan-
dardized methods to evaluate the in vivo effectiveness
of IPTp-SP. Furthermore, the relationship between the
level of SP resistance as measured by molecular markers
and impact of IPTp-SP on birth parameters, or the
treatment response in asymptomatic women receiving
SP for IPTp is not known. Hitherto, monitoring SP re-
sistance was predominantly based on in vivo treatmentresponses among symptomatic children with acute malaria.
However, extrapolation from children to asymptomatic
pregnant women is not appropriate as protective immunity
against P. falciparum malaria is acquired progressively with
cumulative exposure and age. As a result pregnant women
in endemic areas remain typically asymptomatic when
infected and have lower parasites densities than sick
children and as a results have better treatment responses
to anti-malarials, including SP [17,18]. A single arm 42
days in vivo efficacy study of SP was conducted to deter-
mine the parasitological treatment response to SP and the
duration of post-treatment prophylaxis among asymptom-
atic parasitaemic women receiving SP for IPTp in, Mali
and Burkina Faso. The prevalence of molecular markers
for SP resistance was also assessed to explore the relation-
ship between the level of resistance and the treatment
responses.
Methods
Study sites and study period
In Mali, the study was conducted from July 2009 to
March 2010 in 2 district health centres located in the
towns of Kita in the Kayes region in western Mali and in
San in the Segou region situated approximately 500 kilo-
metres east of Kita (Figure 1). Malaria transmission in
the two sites is typical for most of the Sahel region with
highly seasonal transmission restricted to a single period
of three to five months during and shortly after the rainy
season, with peak transmission in October. The degree
of SP resistance is low in these areas and the quintuple
dhfr/dhps haplotype has not been found yet [15], al-
though the dhps581G mutation has been described in
isolation of other mutations in other settings [19,20]. No
previous in-vivo studies among pregnant women were
conducted in Mali.
In Burkina Faso, the study was conducted from January
2010 to December 2011 in five recruitment centres in
Ziniaré town, Oubritenga Province, located 400 km South-
East of the town of San (one of the study sites in Mali).
Malaria transmission is seasonal peaking in September-
October. In 2003, the polymerase chain reaction (PCR)-
adjusted parasitological failure rate by day-28 was 13%
among symptomatic primi- and secundigravida with acute
falciparum malaria in Ouagadougou, located 50 kilometers
from the study site [16].
Participants and procedures
In both countries, pregnant women of all parities with a
gestational age between 16–30 weeks attending for ante-
natal care for their first dose of IPT-SP were included.
Women were screened for malaria infection using HRP2
and pLDH-based combo Rapid Diagnostic Tests (RDTs,
CareStart™Malaria HRP-2/pLDH[Pf/pan] Combo Test)
[21,22]. Women with a positive RDT were then screened
Figure 1 Study sites in Mali (Kita and San) and Burkina Faso (Ziniaré).
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enrolment if they had a positive blood smear, were asymp-
tomatic, were willing to participate in the six-week follow-
up and provided written individual informed consent.
Women were excluded if they had a history of hypersensi-
tivity to SP or its components, a history of prior use of
IPTp-SP during this pregnancy, or a history of receipt of
other anti-malarials or antibiotics with anti-malarial activ-
ity in the previous month.
On enrolment, clinical, obstetric and demographic data
were obtained and information on bed net type and use
recorded. A finger-prick blood sample was taken for
malaria smears, haemoglobin assessment, and dried
blood spots (DBSs) for parasite DNA.
Three tablets of SP containing a total dose of 1,500 mg
sulphadoxine and 75 mg of pyrimethamine were admin-
istered as a single dose on day 0 by the study staff. If
vomiting occurred within 30 minutes after administra-
tion, the full dose was re-administered. Women were
scheduled to be seen again weekly from day 7 onwards
for 42 days for a brief clinical exam, assessment of the
axillary temperature and collection of blood by finger
prick for malaria smears, RDT, and DBSs for PCR. Par-
ticipants were asked to return to the study clinic any
time they felt ill in between the scheduled visits.
Women with positive smear or severe malaria at anytime on or after day 4 were treated according to national
guidelines.
In Mali, the study drug used was manufactured by
Kinapharma limited Ltd, Ghana and in Burkina Faso
this was also from Kinapharma limited Ltd, Ghana and
Medreich limited, India. A sample of 50 tablets from each
batch was assessed for quality using high-performance
liquid chromatography (HPLC) conducted in Atlanta,
GA, USA by the US Centers for Disease Control and
Prevention (CDC) to determine the amount of the ac-
tive ingredient and the dissolution profile. Both brands
passed the dissolution and content analyses criteria set
by the United States Pharmacopeia (USP).Laboratory methods
Haemoglobin concentrations were measured using HemoCue®
(301 System) on days 0, 14, 28 and 42, and on the day of
parasite recurrence. Giemsa-stained blood smears were
assessed in duplicate and if a discrepancy was found
(positive vs negative) the smear was read by a third expert
microscopist. Asexual parasites were counted against 300
leukocytes and densities expressed per mm3 of blood
assuming a leucocyte count of 7,500/mm3. Smears were
declared negative if no parasites were detected in 100
high-power fields.
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Gillings School of Global Public Health, University of
North Carolina, Chapel Hill, NC, USA using genomic
DNA (gDNA) extracted from dried blood spots (DBSs)
stored on Whatman 3 MM filter papers to differentiate
between recrudescence and new infection in follow-up
specimens with parasite recurrence. A standard method
was employed to genotype parasites using polymor-
phisms of the merozoite surface protein-1 (msp-1), mer-
ozoite surface protein-2 (msp-2), and glutamate rich
protein (glurp) genes [23]. The prevalence of genomic
markers of parasite SP resistance, genomic DNA from
all parasitaemic women was pooled by study site (2 in
Mali and 1 in Burkina Faso). Fragments of the dhfr and
dhps genes containing the SNPs of interest were PCR-
amplified from the pooled gDNA from each site to pro-
duce a mixture of gene fragments [24], and these PCR
products were sequenced on a Roche GS Junior next-
generation sequencing system.Figure 2 Study flow chart.Study endpoints classification
The primary outcome was the PCR-unadjusted % of pa-
tients with parasites recurrence by day 42, defined as a
positive diagnostic test (by microscopy) for malaria at any
visit between days 4 and 42. To define treatment failure,
the standard WHO criteria [25] were used.Statistical analysis
Data were analysed using STATA v12 and SPSS version
20. The treatment responses are summarized by weeks
of follow-up. The therapeutic response was estimated
using the Kaplan-Meier product limit formula [26]. In
the PCR-unadjusted analysis, recurrences were treated
as treatment failures and all other events (e.g. with-
drawal or protocol deviations) resulted in censoring at
the time of that event, or at the time of their last
follow-up visit in case of loss to follow-up. A similar strat-
egy was used for the PCR-adjusted analysis except that
Table 1 Baseline characteristics of women enrolled in SP
in vivo efficacy study, Burkina-Faso and Mali
Burkina-Faso Mali All
N=312 N =268 N=580
Age, years,
Mean (SD) 23.6 (5.4) 21.1 (5.1) 22.5 (5.4)
Residing in rural area, n (%) 81 (30.2) 146 (45.2) 222 (38.3)
Knows the date of LMP, n (%) 44 (16.4) 61 (19.6) 105 (18.1)
Pregnancy number
Median (range) 2 (1–8) 2 (1–9) 2 (1–9)
First or second pregnancy, n (%) 204 (65.4) 185 (69.0) 389 (67.1)
Use of a bed net last nighta
Any net, n (%) 187 (60.1) 207 (77.2) 394 (68.1)
ITN, n (%) 171 (55.0) 180 (67.2) 351 (60.6)
Use medicine in first trimester
Any medicine, n (%) 6 (1.9) 25 (9.3) 31(5.3)
Antimalarial, n (%) 2 (0.6) 15 (5.6) 17 (2.9)
Fundal height, cm
Mean (SD) 21.5 (2.9) 21.8 (3.2) 21.7 (3.1)
Gestational age, weeks
Mean (SD) 25.3 (3.1) 25.4 (3.2) 25.3 (3.1)
Maternal height, cm
Mean (SD) 162.7 (6.2) 162.2 (6.3) 162.4 (6.2)
Maternal weight, kgs
Mean (SD) 57.8 (7.5) 56.4 (8.5) 57.2 (8.0)
Haemoglobin, g/dLb
Mean (SD) 10.1 (1.4) 9.6 (1.6) 9.9 (1.5)
Anaemia (Hb <11 /dL), n (%) 225 (72.4) 198 (80.5) 423 (75.9)
Moderate-Severe anaemia
(Hb <8g/dL),
22 (7.1) 40 (16.3) 62 (11.1)
n (%)
Peripheral parasitaemia 623 716 664
GMPD/μl (95% CI) (537–723) (598–859) (592–746)
Notes: Data are n0. (%), unless otherwise indicated.
N, sample size; n, number of events; SD, Standard deviation; LMP, Last
Menstrual Period; ITN, Insecticide Treated Net; cm, centimeters; kgs, kilograms;
g/dL, Gram per deci-Litre; Hb, Haemoglobin; GMPD/μl, Geometric Mean
Parasite Density per microlitre.
aBed net use was not evaluated in 1 subject from Burkina-Faso.
bHaemoglobin was not measured for 1 subject in Burkina-Faso and 22 subjects
in Mali.
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were censored at the time of parasite reappearance [26].
Ethical considerations
The protocol was approved by the Faculty of Medicine,
Pharmacy and Dentistry, University of Bamako, Mali, In-
stitutional Ethical Review Committee, the National Ethical
Review Committee and Ministry of Health, Burkina-Faso,
the University of North Carolina, USA, and the Liverpool
School of Tropical Medicine, UK.
Results
Treatment responses
Overall 580 of 584 women who fulfilled all enrollment cri-
teria were enrolled (99.3%, Figure 2 and Table 1), and 572
of the 580 contributed to the survival analysis. Eight of the
33 women lost to follow-up were not seen after day 0; 3
from Mali and 5 from Burkina-Faso. The remaining 25
were censored on the day they were last seen.
PCR-unadjusted efficacy: Based on microscopy, overall
27 of the 572 women had a recurrence of parasitaemia
by the end of follow-up (Mali 8; Burkina Faso 19). The
cumulative recurrence risks by day 42 estimated by sur-
vival analysis were 4.9% overall, and 3.2% and 6.5% in
Mali and Burkina Faso respectively (Hazard Ratio [HR]
Burkina vs Mali=2.14, 95% CI 0.93-4.90; P=0.070, Table 2
and Figure 3). The recurrence risk was higher among
primi- and secundigravidae (6.4%) than multi-gravidae
(2.2%), HR=3.01 (1.04-8.69; P=0.042) (Figure 4).
PCR-adjusted efficacy: From 26 of the 27 recurrences,
DNA could be extracted and 24 were genotyped success-
fully. This suggested that only 6 of the 24 were recrudes-
cences. The PCR-adjusted cumulative failure rate obtained
by survival analysis was 1.1% overall, and 0.8% in Mali and
1.4% in Burkina-Faso (Figure 3). Overall, median (range)
time to PCR-adjusted failure and to reinfection was 21 (7–35)
and 35 (7–43) days, respectively.
Haematological response: There was a significant in-
crease in the mean haemoglobin concentrations compared
to enrolment at all-time points measured in both coun-
tries and both among primi-, secundi- and multigravida
(Figure 5 and Table 3).
Prevalence of molecular markers for SP resistance at
booking
No dhfr 164L or dhps581G mutations were found in any
of the three sites; the dhps 540E mutation was found in
one site of the two sites Mali, but at a very low prevalence
(Figure 6).
Discussion
SP when given as IPTp to asymptomatic parasitaemic
pregnant women was associated with a high cure rate
and marked increases in haemoglobin concentrations byday 42 in the 3 study sites in Mali and Burkina-Faso.
Overall, only 4.9% of women had a recurrence of parasites
by day 42, and genotyping suggested that the vast majority
of these were reinfections. Overall only 1.1% of treatments
resulted in true treatment failures (recrudescence) and all
of these were asymptomatic. The study shows that SP re-
mains very effective at clearing existing infections when
used as IPTp for malaria prevention in Mali and Burkina-
Faso. This study also showed the potential value of using
in-vivo follow-up to assess the parasitological cure rates
Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali
Characteristics Burkina-Faso Mali All
N=312 N =268 N =580
PCR Days Non- adjusted Adjusted Non- adjusted Adjusted Non- adjusted Adjusted
Day 7:
Number at risk 307 307 265 265 572 572
Failures, n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 2 (0.5) 1 (0.3) 1 (0.4) 1 (0.4) 3 (0.5) 2 (0.3)
ACPR n (%) 305 (99.5) 306 (99.7 264 (99.6) 264 (99.6) 569 (99.5) 570 (99.7)
Day 14:
Number at risk 306 306 260 260 566 566
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 303 (99.0) 304 (99.3 259 (99.6) 259 (99.6 562 (99.3) 563 (99.5)
Day 21:
Number at risk 300 300 259 259 559 559
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 297 (99.0) 298 (99.3) 258 (99.6) 258 (99.6) 542 (99.5) 556 (99.5)
Day 28:
Number at risk 297 297 259 259 556 556
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 7 (2.4) 3 (1.0) 2 (0.8) 2 (0.8) 9 (1.6) 5 (0.9)
ACPR n (%) 290 (97.6) 294 (99.0) 257 (99.2) 257 (99.2) 547 (98.4) 551 (99.1)
Day 35:
Number at risk 295 294a 253 254 548 547a
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0
LPF 14 (4.8) 4 (1.4) 2 (0.8) 2 (0.8) 16 (2.9) 6 (1.1)
ACPR n (%) 281 (95.2) 290 (98.6) 251 (99.2) 252 (99.2) 532 (97.1) 541 (98.9)
Day 42:
Number at risk 293 292a 253 251a,b 546 544c
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
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Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali (Continued)
LPF 19 (6.5) 4 (1.4) 8 (3.2) 2 (0.8) 27 (4.9) 6 (1.1)
ACPR n (%) 274 (93.5) 288 (98.6) 245 (96.8) 249 (99.2) 519 (95.1) 538 (98.9)
Median (range) time in days 35 (7–43)d 21 (7–35)e 42 (7–42)d 18 (7–29)e 35 (7–43)d 21 (7–35)e
Notes: PCR, Polymerase Chain Reaction; ETF, Early Treatment Failure; LCF, Late Treatment Failure; LPF, Late parasitological Failure; ACPR, Adequate Clinical and
Parasitological Response.
aOne PCR inconclusive.
bPCR analysis not conducted for 1 woman with recurrent parasitaemia in Mali.
cPCR inconclusive (1 from Mali, 1 from Burkina) and no PCR analysis available (1 from Mali). These three cases were censored in the survival analysis.
dMedian (range) time to reinfection.
eMedian (range) time to PCR-adjusted failure.
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are due for their first dose of SP for IPTp.
The pooled molecular assays for the surveillance of SP
resistance showed that almost 50% of the parasite popula-
tion in Burkina Faso, but only 9% in San and <1% in Kita,Figure 3 Probability of parasitological failure by microscopy in Burkin
adjusted risk of parasitological failure in Mali and Burkina-Faso. Treatment f
cumulative risk of recurrence was determined using Kaplan-Meier survival a
and panel B represent survival analysis for crude and PCR adjusted analysiscarried the dhfr triple mutations. The pooled deep sequen-
cing of P. falciparum parasitaemia can provide estimates
of the mutant allele frequencies, but does not provide esti-
mates of the quadruple and quintuple dhfr/dhps haplo-
types. Nevertheless, the dhps 540E mutation, which is aa-Faso and Mali. Notes: This graph shows the crude and PCR
ailure was defined according to the standard WHO criteria and the
nalysis. Blue lines represent Mali and red lines Burkina-Faso. Panel A
, respectively.
Figure 4 Probability of parasitological failure by microscopy by gravida group. Notes: (Gravidae 1&2, primi-secundigravida; Gravidae>=3,
multigravida): PCR unadjusted (Panel A) and PCR adjusted (Panel B). This graph shows the crude and PCR adjusted risk of parasitological failure
in both primi-secundigravida and multigravida using Kaplan-Meier survival analysis. Blue lines represents multigravida (gravidae>=3) and the red
lines represent primi-secundigravida (gravidae 1&2), respectively.
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resistance to SP, was present in only one of the two sites
of Mali and at very low frequency (0.73%, 95% CI 0.58-
0.87). The mutation at dhfr codon 164L and dhps codon
581G conferring very high-level resistance to SP were
absent. In addition, there were several novel mutations
in dhps, which were limited to a very low frequency.
Their clinical and biological significance is unknown,
but their quantification underscores the ability of the
pooled genotyping approach to uncover low-level sub-
populations of parasites.
The 1.4% failure rate in Burkina Faso among asymp-
tomatic women in this study is in contrast to the 13%
PCR-adjusted failure rate by day-28 observed in the previ-
ous in-vivo study among symptomatic pregnant women
conducted in 2003 in an area located ≈32 miles south
from the current site [16]. The average parasite densitiesin the previous study were 10 fold higher than in the
current study, illustrating the differences in treatment
responses when SP is used as IPTp in asymptomatic
women with predominantly low-grade parasitaemia vs.
acutely ill women requiring case-management drugs.
This may in part explain the earlier findings from ran-
domized controlled trials that IPTp-SP remained sur-
prisingly effective in areas with moderate to high levels
of SP resistance [2,5].
The study provides an important contribution to the
understanding of the predictive value of the frequency of
population estimates of the different dhfr and dhps mu-
tations on the efficacy of SP in clearing malaria infection
among asymptomatic pregnant women, especially when
our results are compared against day 42 failure rates in
areas with higher resistance. For example, the dhfr triple
mutation (Ile51+Arg59+Asn108) was present in almost
Figure 5 Increase in haemoglobin concentrations by country in all gravida. Notes: (top panel) and by gravidae group (bottom panel).
Analysis was done with repeated measures Generalized Estimating Equation (GEE), adjusted for the baseline hemoglobin levels on Day-0. Black
squares or diamonds represent the point estimates and vertical lines the corresponding 95% confidence intervals.
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1.4% of the treatments recrudesced by day 42. The dhfr
triple mutation is known to confer intense pyrimethamine
resistance in vitro [27] and is associated with an approxi-
mate 1,000-fold reduction in pyrimethamine susceptibility
[28] and with an increased risk of SP treatment failure in
children with acute malaria [29-31]. These combined data
suggests that parasite densities and immunity contribute
importantly to parasite clearance, which in turn influences
the association of treatment outcome with dhfr and dhps
alleles.
It is likely that the results of this study are representative
for large parts of West and Central Africa that have a
similar low geographic prevalence of the dhfr/dhps quad-
ruple or quintuple mutations reflecting low and mid-levelresistance to SP [7]. A key question is whether this situ-
ation can be sustained or whether further development of
SP drug resistance is inevitable in this region. Mutations
arise under antifolate pressure in a stepwise fashion, with
successive mutations conferring higher levels of resistance
[32]. Previous studies from Ghana showed a rapid increase
in the prevalence of the triple-mutant dhfr alleles among
falciparum isolated from pregnant women in an area
where pyrimethamine prophylaxis (as mono-therapy) was
used 6 to 8 years previously for the prevention of malaria
[33]. Some fitness-reducing mutations, such as the dhfr
I164L can only be sustained under conditions of sustained
drug pressure. The switch from SP as first-line treatment
for symptomatic malaria in the general population to an
ACT will have hada marked impact on reducing SP drug
Table 3 Haemoglobin concentration and anaemia among women enrolled in Burkina-Faso and Mali
Characteristics Burkina-Faso Mali All
Day 0
N 311 246 557
Mean haemoglobin (SD), g/dl 10.1 (1.4) 9.6 (1.6) 9.9 (1.5)
Anaemia (<11 g/dl), n (%) 225 (72.4) 198 (80.5) 423 (75.9)
Day 14
N 301 237 538
Mean haemoglobin (SD), g/dl 10.2 (1.3) 10.1 (1.4) 10.2 (1.3)
Anaemia (<11 g/dl), n (%) 208 (69.1) 177 (74.7) 385 (71.6)
Mean difference, 95% CIa 0.13 (0.004, 0.26) 0.44 (0.28, 0.59) 0.26 (0.16, 0.36)
Risk ratio, 95% CIb 0.96 (0.86, 1.06) 0.93 (0.84, 1.02) 0.94 (0.88, 1.01)
Day 28
N 290 244 534
Mean haemoglobin (SD), g/dl 10.7 (1.2) 10.6 (1.2) 10.6 (1.2)
Anaemia (<11 g/dl), n (%) 171 (59.0) 153 (62.7) 325 (60.7)
Mean difference, 95% CIa 0.60 (0.46,0.74) 0.87 (0.69, 1.06) 0.72 (0.61, 0.83)
Risk ratio, 95% CIb 0.82 (0.72, 0.92) 0.78 (0.70, 0.87) 0.80 (0.74, 0.87
Day 42
N 265 249 514
Mean haemoglobin (SD), g/dl 11.0 (1.2) 10.9 (1.3) 10.9 (1.3)
Anaemia (<11g/dl), n (%) 127 (47.9) 120 (48.2) 247 (48.1)
Mean difference, 95% CIa 0.87 (0.65, 1.09) 1.30 (1.11, 1.49) 1.06 (0.93, 1.18)
Risk ratio, 95% CIb 0.66 (0.57, 0.77) 0.60 (0.52, 0.69) 0.63 (0.57, 0.70)
Notes:
N, sample size; n, number of events; SD, standard deviation; g/dl, gram per decilitre; CI, confidence interval.
aMean difference and 95% confidence interval for each time that haemoglobin was measured using day 0 as reference category.
bRisk ratio and 95% confidence interval for each time that haemoglobin was measured using day 0 as reference category, adjusted for gravida and site (all), and
for gravida (in each country).
Coulibaly et al. Malaria Journal 2014, 13:41 Page 10 of 13
http://www.malariajournal.com/content/13/1/41pressure in the population [34]. However, the effect of
continued use of cotrimoxazole in the treatment of diar-
rheal and respiratory infectious diseases in children should
also be considered, although this drug did not appear to
select for SP-resistance parasites [19]. Modelling of the
impact of the introduction of IPTi in infants suggest that
use of SP in small target populations such as infants or
pregnant women may not sustain sufficient drug pressure
to impact on the spread of drug resistance. This was also
suggested in field studies in Mali [35]. However, many
West African countries including Mali and Burkina are
seeking to implement Seasonal Malaria Chemoprevention
(SMC) [36] in children which would provide presumptive
treatment over the course of the transmission season to
a much larger fraction of the population. Although, the
combination of amodiaquine (AQ) and SP is one of the
main candidate anti-malarials for SMC, it is unclear if
the introduction of this strategy will indeed increase SP
drug pressure. The effect of SMC on drug pressure may
be minimal if implemented on a large enough scale to
impact on malaria transmission and the total parasitebiomass in the SMC population, especially if an ACT is
used as case-management for clinical episodes caused
by any SP resistant parasites that may have escaped the
drug action of SMC. It will be clearly important to
monitor the prevalence of molecular markers of parasite
resistance to SP, especially in areas where SP is used for
both IPTp and SMC.
This investigation found a high prevalence of anaemia
and showed that SP treatment was associated with a
marked increase in mean haemoglobin levels by day 42.
The fact that the impact was most pronounced in the
primi,- and secundigravidae, the group most susceptible
to adverse effect of malaria, may indicate that even
these asymptomatic infections are an important cause
of maternal anaemia in this subgroup. These findings
are consistent with previous findings that showed IPTp
has a marked beneficial impact on moderate-to-severe
anaemia in Mali [15,37].
The study was limited by the lack of genotyping of para-
sites from individual women for molecular markers of SP
resistance, and the genomic DNA from pooled sequencing
Figure 6 Prevalence of SP resistance molecular makers in Burkina-Faso and Mali among parasitaemic women at their antenatal
booking visit (pre-SP). Notes: dhfr /dhps alleles (Top panel) and dhfr haplotypes (Bottom panel). Mutant allele frequencies are represented in the
top panel graph by horizontal bars. Lines depict the 95% confidence intervals. The presence of “0” represents the absence of point mutations for
a designed codon. The bottom panel represents the frequency of dhfr haplotypes (N51I, C59R, and S108N) per country.
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tween treatment efficacy or the haematological response
in individual women and SP resistance molecular markers.Conclusion
This is among the first studies to examine the 42-day
in vivo response of IPTp-SP in asymptomatic women in
areas with low level of SP resistance in West Africa.
Despite growing concerns about the impact of SP resist-
ance in east and southern Africa, this study shows that
SP remains effective at clearing existing infections and
improving haemoglobin concentration when provided as
IPTp to asymptomatic pregnant women in Mali and
Burkina-Faso. SP has many attributes that makes it anexcellent candidate for IPTp, and it is thus likely that it
could remain the drug of choice for IPTp in this region
for the foreseeable future. However continued monitor-
ing of SP resistance over the next years in this region
coupled with monitoring of IPTp-SP effectiveness on
birth parameters is essential.
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